BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 35090034)

  • 21. Selective gene dependencies in MYCN-amplified neuroblastoma include the core transcriptional regulatory circuitry.
    Durbin AD; Zimmerman MW; Dharia NV; Abraham BJ; Iniguez AB; Weichert-Leahey N; He S; Krill-Burger JM; Root DE; Vazquez F; Tsherniak A; Hahn WC; Golub TR; Young RA; Look AT; Stegmaier K
    Nat Genet; 2018 Sep; 50(9):1240-1246. PubMed ID: 30127528
    [TBL] [Abstract][Full Text] [Related]  

  • 22. GD2 redirected CAR T and activated NK-cell-mediated secretion of IFNγ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape.
    Caforio M; Sorino C; Caruana I; Weber G; Camera A; Cifaldi L; De Angelis B; Del Bufalo F; Vitale A; Goffredo BM; De Vito R; Fruci D; Quintarelli C; Fanciulli M; Locatelli F; Folgiero V
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737337
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The MYCN oncoprotein as a drug development target.
    Lu X; Pearson A; Lunec J
    Cancer Lett; 2003 Jul; 197(1-2):125-30. PubMed ID: 12880971
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reciprocal antagonistic regulation of N-myc mRNA by miR‑17 and the neuronal-specific RNA-binding protein HuD.
    Samaraweera L; Spengler BA; Ross RA
    Oncol Rep; 2017 Jul; 38(1):545-550. PubMed ID: 28560387
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ID2 expression in neuroblastoma does not correlate to MYCN levels and lacks prognostic value.
    Vandesompele J; Edsjö A; De Preter K; Axelson H; Speleman F; Påhlman S
    Oncogene; 2003 Jan; 22(3):456-60. PubMed ID: 12545167
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD133 expression and MYCN amplification induce chemoresistance and reduce average survival time in pediatric neuroblastoma.
    Zhong ZY; Shi BJ; Zhou H; Wang WB
    J Int Med Res; 2018 Mar; 46(3):1209-1220. PubMed ID: 29322842
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype.
    Xu M; Sun M; Zhang X; Nguyen R; Lei H; Shern JF; Thiele CJ; Liu Z
    Cancer Res; 2023 Mar; 83(5):686-699. PubMed ID: 36598365
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The deubiquitinase USP28 maintains the expression of the transcription factor MYCN and is essential in neuroblastoma cells.
    Li J; Peng J; Wu L; Shen X; Zhen X; Zhang Y; Ma H; Xu Y; Xiong Q; Zhu Q; Zhang P
    J Biol Chem; 2023 Jul; 299(7):104856. PubMed ID: 37230388
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heterogeneity of MYCN amplification in neuroblastoma at diagnosis, treatment, relapse, and metastasis.
    Marrano P; Irwin MS; Thorner PS
    Genes Chromosomes Cancer; 2017 Jan; 56(1):28-41. PubMed ID: 27465929
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of Genetic Predisposition for MYCN-Amplified Neuroblastoma.
    Hungate EA; Applebaum MA; Skol AD; Vaksman Z; Diamond M; McDaniel L; Volchenboum SL; Stranger BE; Maris JM; Diskin SJ; Onel K; Cohn SL
    J Natl Cancer Inst; 2017 Oct; 109(10):. PubMed ID: 29117357
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The PLAGL2/MYCN/miR-506-3p interplay regulates neuroblastoma cell fate and associates with neuroblastoma progression.
    Zhao Z; Shelton SD; Oviedo A; Baker AL; Bryant CP; Omidvarnia S; Du L
    J Exp Clin Cancer Res; 2020 Feb; 39(1):41. PubMed ID: 32087738
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas.
    Westermann F; Muth D; Benner A; Bauer T; Henrich KO; Oberthuer A; Brors B; Beissbarth T; Vandesompele J; Pattyn F; Hero B; König R; Fischer M; Schwab M
    Genome Biol; 2008 Oct; 9(10):R150. PubMed ID: 18851746
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Venetoclax-based Rational Combinations are Effective in Models of
    Dalton KM; Krytska K; Lochmann TL; Sano R; Casey C; D'Aulerio A; Khan QA; Crowther GS; Coon C; Cai J; Jacob S; Kurupi R; Hu B; Dozmorov M; Greninger P; Souers AJ; Benes CH; Mossé YP; Faber AC
    Mol Cancer Ther; 2021 Aug; 20(8):1400-1411. PubMed ID: 34088831
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ALK expression, prognostic significance, and its association with MYCN expression in MYCN non-amplified neuroblastoma.
    Somasundaram DB; Aravindan S; Gupta N; Yu Z; Baker A; Aravindan N
    World J Pediatr; 2022 Apr; 18(4):285-293. PubMed ID: 35132576
    [No Abstract]   [Full Text] [Related]  

  • 35. Unveiling MYCN regulatory networks in neuroblastoma via integrative analysis of heterogeneous genomics data.
    Hsu CL; Chang HY; Chang JY; Hsu WM; Huang HC; Juan HF
    Oncotarget; 2016 Jun; 7(24):36293-36310. PubMed ID: 27167114
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Histone Methyltransferase DOT1L Promotes Neuroblastoma by Regulating Gene Transcription.
    Wong M; Tee AEL; Milazzo G; Bell JL; Poulos RC; Atmadibrata B; Sun Y; Jing D; Ho N; Ling D; Liu PY; Zhang XD; Hüttelmaier S; Wong JWH; Wang J; Polly P; Perini G; Scarlett CJ; Liu T
    Cancer Res; 2017 May; 77(9):2522-2533. PubMed ID: 28209620
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma.
    Bosse KR; Raman P; Zhu Z; Lane M; Martinez D; Heitzeneder S; Rathi KS; Kendsersky NM; Randall M; Donovan L; Morrissy S; Sussman RT; Zhelev DV; Feng Y; Wang Y; Hwang J; Lopez G; Harenza JL; Wei JS; Pawel B; Bhatti T; Santi M; Ganguly A; Khan J; Marra MA; Taylor MD; Dimitrov DS; Mackall CL; Maris JM
    Cancer Cell; 2017 Sep; 32(3):295-309.e12. PubMed ID: 28898695
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MYCN oncoprotein targets and their therapeutic potential.
    Bell E; Chen L; Liu T; Marshall GM; Lunec J; Tweddle DA
    Cancer Lett; 2010 Jul; 293(2):144-57. PubMed ID: 20153925
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma.
    Rounbehler RJ; Li W; Hall MA; Yang C; Fallahi M; Cleveland JL
    Cancer Res; 2009 Jan; 69(2):547-53. PubMed ID: 19147568
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biological Insight and Recent Advancement in the Treatment of Neuroblastoma.
    Rivera Z; Escutia C; Madonna MB; Gupta KH
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239815
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.